We ran 17 proof-of-concept systems before committing to a production direction. That number sounds excessive only if you think the goal of a POC is to confirm enthusiasm. In regulated healthcare, the goal is to expose weakness before that weakness reaches a real workflow.
The difference matters because the cost of a weak AI decision in healthcare is not only technical debt. It can be clinical confusion, support burden, regulatory delay, or loss of trust from partners who were promised a system that was ready sooner than it really was.
Each POC should answer one serious question
The most useful POCs are narrow. One might test integration behavior with a partner environment. Another might test whether a model output is operationally interpretable. Another might test whether a workflow can generate evidence useful later in ISO 13485 documentation and risk management.
When a POC tries to answer everything at once, it usually answers nothing clearly.
Clinical and regulatory realities change the bar
In regulated healthcare, a result that looks acceptable in a demo can still be unusable in production. Latency may be unstable. Failure handling may be weak. Data quality assumptions may be unrealistic. Traceability may be missing. That is why validation has to judge both system behavior and system governability.
Teams that skip this stage are not moving faster. They are postponing the moment when reality becomes expensive.
Evidence reuse is part of good validation
Another advantage of disciplined POCs is that they can produce artifacts useful later: test designs, failure records, integration observations, and quality evidence. In a regulated environment, that reuse matters. Validation work should feed the eventual production case, not sit in a forgotten slide deck.
That was one reason the sequence of 17 production POCs and 15 prototype solutions produced real strategic value across Singapore, Japan, Vietnam, and India.
In healthcare AI, the validation bar is not “does it work in the demo?” It is “does it work reliably enough that a regulated system can defend it?”
Why leaders should care
Engineering leaders often inherit pressure to collapse validation because stakeholders are impatient. My experience is that shortening the wrong stage rarely reduces total time. It usually moves the same cost into a more dangerous part of the program.
Validation is not hesitation. In regulated healthcare, it is one of the few places where disciplined patience creates actual speed later.